Here’s a stark reality: Microsatellite-stable (MSS) metastatic colorectal cancer remains one of the most stubborn challenges in oncology, with limited treatment options and poor outcomes after standard therapies fail. But a new player is stepping onto the stage, and it’s turning heads. Enter zanzalintinib, a next-generation multi-kinase inhibitor developed by Exelixis, designed to tackle the very mechanisms that make MSS colorectal cancer so resistant to treatment. And this is the part most people miss: while nearly 95% of colorectal cancers are MSS, these tumors are notoriously resistant to immunotherapy, leaving clinicians with few options beyond regorafenib or trifluridine/tipiracil—both of which offer modest benefits at best and come with significant side effects (Grothey et al., Lancet, 2013). But here’s where it gets controversial: Could zanzalintinib be the game-changer we’ve been waiting for in this hard-to-treat population? Let’s dive in.
Why MSS Colorectal Cancer is So Tough to Treat
MSS colorectal cancer is aggressive, immunologically 'cold,' and largely unresponsive to checkpoint inhibitors. Its key features—low mutation burden, high angiogenesis, robust immune exclusion, and strong epithelial-mesenchymal transition (EMT) signatures—create a perfect storm of resistance. These tumors also upregulate MET and AXL signaling, pathways that drive metastasis and therapy resistance. The question is: Can we outsmart these mechanisms?
How Zanzalintinib Works
Zanzalintinib (formerly XL092) is an oral tyrosine kinase inhibitor that targets VEGFR2, MET, AXL, and the TAM kinase family. By simultaneously blocking these pathways, it tackles angiogenesis, tumor invasiveness, metastatic potential, and immune suppression. For instance, inhibiting VEGFR2 and MET counteracts the escape mechanisms often seen with earlier anti-angiogenic agents, while targeting AXL reduces EMT, a key driver of metastasis. Early studies suggest zanzalintinib’s shorter half-life and improved kinase selectivity may lead to better tolerability compared to its predecessor, cabozantinib (Gao et al., Clin Cancer Res, 2021). But is this enough to make a real difference in patients?
The STELLAR-303 Trial: A Breakthrough?
The phase III STELLAR-303 trial put zanzalintinib to the test in heavily pretreated MSS metastatic colorectal cancer patients who had progressed on standard therapies, including fluoropyrimidines, oxaliplatin, irinotecan, and bevacizumab. Patients were randomized to receive either zanzalintinib or regorafenib, the current standard of care. The results? Zanzalintinib demonstrated improved overall survival (OS) and progression-free survival (PFS) compared to regorafenib, marking the first significant advance in MSS colorectal cancer in nearly a decade. This benefit was consistent across subgroups, including patients with liver metastases, who typically respond poorly to immunotherapy (STELLAR-303 Investigators, ASCO GI, 2025). But here’s the kicker: While detailed OS and PFS numbers are pending, the trial showed more durable responses and fewer early discontinuations with zanzalintinib. Is this the beginning of a new era in MSS treatment?
Safety and Tolerability: A Step Forward?
Zanzalintinib’s side effect profile aligns with other anti-angiogenic therapies, with hypertension, fatigue, diarrhea, and hand-foot syndrome being the most common. However, its toxicity appears more manageable than regorafenib, which is often limited by severe hand-foot syndrome and gastrointestinal issues. The drug’s optimized kinase selectivity and shorter half-life allow for easier dose adjustments and fewer high-grade adverse events. But does this translate to better quality of life for patients?
The Bigger Picture: Clinical Significance
Zanzalintinib addresses a critical unmet need in MSS metastatic colorectal cancer by targeting the very pathways that drive disease progression. Its multi-pathway inhibition offers a biologically rational approach in a setting where traditional cytotoxic therapies fall short. But here’s a thought-provoking question: Could zanzalintinib become the new standard of care for patients who progress on first- and second-line therapies? The STELLAR-303 results certainly suggest so.
Future Directions: Combinations and Beyond
Preclinical data hint at zanzalintinib’s potential in combination with checkpoint inhibitors, particularly in MSS colorectal cancer, where immune resistance is a major hurdle (Feng et al., Cancer Res, 2022). Additionally, the drug is being explored in other MET- or AXL-driven tumors, such as renal cell carcinoma and hepatocellular carcinoma. But will these combinations live up to the hype? Only time—and more trials—will tell.
Conclusion: A New Hope?
Zanzalintinib represents a meaningful step forward in MSS metastatic colorectal cancer, offering improved survival, better tolerability, and a mechanism that tackles multiple resistance pathways. But here’s the ultimate question: As we await more data, will zanzalintinib redefine targeted therapy in this challenging disease? Share your thoughts in the comments—do you think this drug has what it takes to transform the treatment landscape?
